Anti-Heat Shock Protein 27 Antibody Levels and Diabetic Complications in the EURODIAB Study

D. Burt, G. Bruno, N. Chaturvedi, C. Schalkwijk, C.D. Stehouwer, D.R. Witte, J.H. Fuller, S. Pinach, P. Cavallo Perin, G. Gruden

    Research output: Contribution to journalArticleAcademicpeer-review

    12 Citations (Scopus)

    Abstract

    Objective: To assess whether serum anti-heat shock protein 27 (HSP27) antibody levels are associated with micro- and macrovascular complications of type 1 diabetes. Research Design and Methods: Anti-HSP27 IgG antibody levels were measured in 531 type 1 diabetic subjects recruited as part of the cross-sectional analysis of the EURODIAB Prospective Complications Study. Case subjects (n=363) were defined as those with one or more diabetic complications and control subjects (n=168) as those with no evidence of any diabetic complication. Results: Anti-HSP27 levels were comparable in cases and control subjects [19.6 AU/ml (11.3-32.7) vs. 20.4 AU/ml (11.7-35.3), geometric mean, (interquartile range)] and there was no correlation between HSP27 and anti-HSP27 levels (r=0.01, p=0.81). In logistic regression analysis anti-HSP27 was not associated with the presence of complications, even after adjustment for main risk factors. Conclusions: Anti-HSP27 antibody levels are not a marker of vascular complications in type 1 diabetes.
    Original languageEnglish
    Pages (from-to)1269-1271
    JournalDiabetes Care
    Volume32
    Issue number7
    DOIs
    Publication statusPublished - 1 Jan 2009

    Cite this

    Burt, D., Bruno, G., Chaturvedi, N., Schalkwijk, C., Stehouwer, C. D., Witte, D. R., Fuller, J. H., Pinach, S., Cavallo Perin, P., & Gruden, G. (2009). Anti-Heat Shock Protein 27 Antibody Levels and Diabetic Complications in the EURODIAB Study. Diabetes Care, 32(7), 1269-1271. https://doi.org/10.2337/dc08-2271